Efficacy and safety of neoadjuvant immunotherapy protocols and cycles for non-small cell lung cancer: a systematic review and meta-analysis.

ABSTRACT:

Objectives

This study evaluated the use of different neoadjuvant immunotherapy cycles and regimens for non-small cell lung cancer.

Materials and methods

Databases were searched for articles published up until December 2023. Data on the major pathologic response (MPR), complete pathologic response (pCR), radiological response, treatment-related adverse events (TRAEs), serious adverse events (SAEs), surgical resection, surgical complications, R0 resection, and conversion to thoracotomy were collected. A subgroup analysis was performed according to the treatment regimens and cycles. Stata/MP software was used for statistical analyses.

Results

In total, 2430 individuals were assessed from 44 studies. Compared with those following neoadjuvant immunotherapy alone (MPR/pCR/T

SUBMITTER: Wang H 

PROVIDER: S-EPMC10824986 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature